Home > Publications database > Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies. > print

001     169023
005     20240229133636.0
024 7 _ |a 10.1038/s41417-021-00347-z
|2 doi
024 7 _ |a pmid:34045664
|2 pmid
024 7 _ |a 0929-1903
|2 ISSN
024 7 _ |a 1476-5500
|2 ISSN
024 7 _ |a altmetric:110680390
|2 altmetric
037 _ _ |a DKFZ-2021-01191
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Denisova, Evgeniya
|0 P:(DE-He78)1de6abf55d62da5d66dcc1fb53ebb7f8
|b 0
|e First author
|u dkfz
245 _ _ |a Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
260 _ _ |a New York, NY
|c 2022
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1656426764_18200
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B330# / 2022 Jun;29(6):697-708
520 _ _ |a Malignant sweat gland tumours are rare, with the most common form being Eccrine porocarcinoma (EP). To investigate the mutational landscape of EP, we performed whole-exome sequencing (WES) on 14 formalin-fixed paraffin-embedded samples of matched primary EP and healthy surrounding tissue. Mutational profiling revealed a high overall median mutation rate. This was attributed to signatures of mutational processes related to ultraviolet (UV) exposure, APOBEC enzyme dysregulation, and defective homologous double-strand break repair. All of these processes cause genomic instability and are implicated in carcinogenesis. Recurrent driving somatic alterations were detected in the EP candidate drivers TP53, FAT2, CACNA1S, and KMT2D. The analyses also identified copy number alterations and recurrent gains and losses in several chromosomal regions including that containing BRCA2, as well as deleterious alterations in multiple HRR components. In accordance with this reduced or even a complete loss of BRCA2 protein expression was detected in 50% of the investigated EP tumours. Our results implicate crucial oncogenic driver pathways and suggest that defective homologous double-strand break repair and the p53 pathway are involved in EP aetiology. Targeting of the p53 axis and PARP inhibition, and/or immunotherapy may represent promising treatment strategies.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Westphal, Dana
|b 1
700 1 _ |a Surowy, Harald M
|b 2
700 1 _ |a Meier, Friedegund
|b 3
700 1 _ |a Hutter, Barbara
|0 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
|b 4
|u dkfz
700 1 _ |a Reifenberger, Julia
|b 5
700 1 _ |a Rütten, Arno
|b 6
700 1 _ |a Schulz, Alexander
|b 7
700 1 _ |a Sergon, Mildred
|b 8
700 1 _ |a Ziemer, Mirjana
|b 9
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 10
|u dkfz
700 1 _ |a Betz, Regina C
|0 0000-0001-5024-3623
|b 11
700 1 _ |a Redler, Silke
|0 0000-0002-0991-252X
|b 12
773 _ _ |a 10.1038/s41417-021-00347-z
|0 PERI:(DE-600)2004200-0
|n 6
|p 697-708
|t Cancer gene therapy
|v 29
|y 2022
|x 1476-5500
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169023
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1de6abf55d62da5d66dcc1fb53ebb7f8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER GENE THER : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER GENE THER : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-He78)B330-20160331
|k B330
|l Angewandte Bioinformatik
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B330-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21